High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry

Clinica Chimica Acta

Volumn 412, Issue 3-4, 2011, Pages 358-364

  Corona, Giuseppe ^a   Elia, Caterina ^a   Casetta, Bruno ^b   Frustaci, Sergio ^a   Toffoli, Giuseppe ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b MDS SCIEX   (Canada)

Author keywords

Docetaxel; LC MS MS; On line extraction; Therapeutic drug monitoring

Indexed keywords

CAPECITABINE; DOCETAXEL; OXALIPLATIN; PACLITAXEL;

ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG PURIFICATION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, LIQUID; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; LIMIT OF DETECTION; LINEAR MODELS; ONLINE SYSTEMS; TANDEM MASS SPECTROMETRY; TAXOIDS; TIME FACTORS;

EID: 78650231840     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.11.010     Document Type: Article

References (32)

1. Lavelle F., Bissery M.C., Combeau C., Riou J.F., Vrignaud P., Andre S. Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 1995, 22:3-16.
2. Gilbert D.C., Parker C. Docetaxel for the treatment of prostate cancer. Future Oncol 2005, 1:307-314.
3. Lyseng-Williamson K.A., Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005, 65:2513-2531.
4. Saloustros E., Georgoulias V. Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2008, 8:1207-1222.
5. Salminen E., Bergman M., Huhtala S., Ekholm E. Docetaxel: standard recommended dose of 100mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-a phase II single-center study. J Clin Oncol 1999, 17:1127.
6. Burstein H.J., Manola J., Younger J., et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000, 18:1212-1219.
7. Kuroi K., Bando H., Saji S., Toi M. Weekly schedule of docetaxel in breast cancer: evaluation of response and toxicity. Breast Cancer 2003, 10:10-14.
8. Ciccolini J., Catalin J., Blachon M.F., Durand A. Rapid high-performance liquid chromatographic determination of docetaxel (Taxotere) in plasma using liquid-liquid extraction. J Chromatogr B Biomed Sci Appl 2001, 759:299-306.
9. Garg M.B., Ackland S.P. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J Chromatogr B Biomed Sci Appl 2000, 748:383-388.
10. Grozav A.G., Hutson T.E., Zhou X., Bukowski R.M., Ganapathi R., Xu Y. Rapid analysis of docetaxel in human plasma by tandem mass spectrometry with on-line sample extraction. J Pharm Biomed Anal 2004, 36:125-131.
11. Guitton J., Cohen S., Tranchand B., et al. Quantification of docetaxel and its main metabolites in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2005, 19:2419-2426.
12. Gustafson D.L., Long M.E., Zirrolli J.A., et al. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 2003, 52:159-166.
13. Hou W., Watters J.W., McLeod H.L. Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 804:263-267.
14. Huang Q., Wang G.J., Sun J.G., Hu X.L., Lu Y.H., Zhang Q. Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2007, 21:1009-1018.
15. Kuppens I.E., van Maanen M.J., Rosing H., Schellens J.H., Beijnen J.H. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry. Biomed Chromatogr 2005, 19:355-361.
16. Loos W.J., Verweij J., Nooter K., Stoter G., Sparreboom A. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997, 693:437-441.
17. Mortier K.A., Renard V., Verstraete A.G., Van Gussem A., Van Belle S., Lambert W.E. Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid. Anal Chem 2005, 77:4677-4683.
18. Rouini M.R., Lotfolahi A., Stewart D.J., et al. A rapid reversed phase high performance liquid chromatographic method for the determination of docetaxel (Taxotere) in human plasma using a column switching technique. J Pharm Biomed Anal 1998, 17:1243-1247.
19. Sparreboom A., Zhao M., Brahmer J.R., Verweij J., Baker S.D. Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 773:183-190.
20. Vergniol J.C., Bruno R., Montay G., Frydman A. Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method. J Chromatogr 1992, 582:273-278.
21. Wang L.Z., Goh B.C., Grigg M.E., Lee S.C., Khoo Y.M., Lee H.S. A rapid and sensitive liquid chromatography/tandem mass spectrometry method for determination of docetaxel in human plasma. Rapid Commun Mass Spectrom 2003, 17:1548-1552.
22. Parise R.A., Ramanathan R.K., Zamboni W.C., Egorin M.J. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 783:231-236.
23. Richheimer S.L., Tinnermeier D.M., Timmons D.W. High-performance liquid chromatographic assay of taxol. Anal Chem 1992, 64:2323-2326.
24. US Food and Drug Administration Center for Drug Evaluation and Research Guidance for the industry: bioanalytical method validation. US Food and Drug Administration http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
25. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003, 75:3019-3030.
26. Mortier K.A., Verstraete A.G., Zhang G.F., Lambert W.E. Enhanced method performance due to a shorter chromatographic run-time in a liquid chromatography-tandem mass spectrometry assay for paclitaxel. J Chromatogr A 2004, 1041:235-238.
27. Yan Z., Maher N., Torres R., et al. Isobaric metabolite interferences and the requirement for close examination of raw data in addition to stringent chromatographic separations in liquid chromatography/tandem mass spectrometric analysis of drugs in biological matrix. Rapid Commun Mass Spectrom 2008, 22:2021-2028.
28. Chiorean E.G., Porter J.M., Foster A.E., et al. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane-naive malignancies. Clin Cancer Res 2008, 14:1131-1137.
29. Fakih M.G., Creaven P.J., Ramnath N., et al. Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors. Clin Cancer Res 2005, 11:5942-5949.
30. Ramanathan R.K., Ramalingam S., Egorin M.J., et al. Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies. Cancer Chemother Pharmacol 2005, 55:354-360.
31. Schwartz E.L. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009, 15:2594-2601.
32. Magera M.J., Lacey J.M., Casetta B., Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 1999, 45:1517-1522.